Jeremy Livianu
Conseiller Juridique Général chez UPHEALTH, INC.
Profil
Jeremy Livianu is currently the Chief Legal Officer at UpHealth, Inc. He previously worked as the Director of Legal Affairs at Nevro Corp., Corporate Counsel at Tethys Bioscience, Inc., General Counsel at Establishment Labs Holdings, Inc., and Secretary, Vice President & General Counsel at Cutera, Inc. He received his undergraduate degree from the University of California San Diego and his doctorate from George Washington University Law School.
Postes actifs de Jeremy Livianu
| Sociétés | Poste | Début |
|---|---|---|
| UPHEALTH, INC. | Conseiller Juridique Général | 01/03/2023 |
Anciens postes connus de Jeremy Livianu
| Sociétés | Poste | Fin |
|---|---|---|
| CUTERA, INC. | Conseiller Juridique Général | 01/12/2022 |
| ESTABLISHMENT LABS HOLDINGS INC. | Conseiller Juridique Général | 01/10/2020 |
Tethys Bioscience, Inc.
 Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Conseiller Juridique Général | - |
| NEVRO CORP. | Conseiller Juridique Général | - |
Formation de Jeremy Livianu
| George Washington University Law School | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ESTABLISHMENT LABS HOLDINGS INC. | Health Technology |
| NEVRO CORP. | Health Technology |
| CUTERA, INC. | Health Technology |
| UPHEALTH, INC. | Health Services |
| Entreprise privées | 1 |
|---|---|
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
